Tokyo, Japan

Takanori Yokota

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):

Title: Innovations and Contributions of Takanori Yokota

Introduction

Takanori Yokota, based in Tokyo, Japan, is a prominent inventor known for his significant contributions to the field of nucleic acid technologies. With a remarkable portfolio of 19 patents, he has made strides in developing solutions for efficient drug delivery to the nervous system, overcoming the challenges posed by the blood-brain barrier (BBB).

Latest Patents

Among his most recent innovations are notable patents focused on nucleic acid agents. One of his patents involves a BBB-crossing lipid ligand of heteronucleic acid. This invention is designed to facilitate the delivery of antisense nucleic acids directly to the central nervous system, enabling targeted modulation of transcriptional products in challenging environments where traditional drug delivery methods fail. Another groundbreaking patent describes a nucleic acid with reduced toxicity—this low-toxicity antisense medicine aims to modulate expression in the central nervous system and other areas without adverse effects. Both inventions highlight his commitment to advancing medical science through innovative nucleic acid therapies.

Career Highlights

Takanori Yokota has held key positions in prestigious institutions, notably at Tokyo Medical and Dental University and Osaka University. His work at these universities has allowed him to collaborate closely with other leading researchers and push the boundaries of what is possible in his field.

Collaborations

Throughout his career, Yokota has collaborated with esteemed colleagues such as Kazutaka Nishina and Hidehiro Mizusawa. These partnerships have been instrumental in advancing research and facilitating the development of groundbreaking inventions that address critical medical challenges.

Conclusion

Takanori Yokota continues to be a driving force in the innovation of nucleic acid-based therapies. His ongoing research and numerous patents are a testament to his expertise and dedication to improving health outcomes through scientific advancements. As he progresses in his career, the impact of his work is expected to resonate within the medical research community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…